MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$727M
Free Cash flow
$302M
Unit: Million (M) dollars
Positive Cash Flow Breakdown
Asset write-offs and impairments
Proceeds from redemptions/sales ...
Proceeds from sale of investment...
Others
Negative Cash Flow Breakdown
Purchases of short-term investme...
Cash dividends paid
Net gain from the sale of invest...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-28
2026-03-29
2025-12-31
2025-09-28
Net income from continuing operations before allocation to noncontrolling interests
-246
2,709
-1,640
3,551
Depreciation and amortization
1,622
1,613
1,687
1,662
Asset write-offs and impairments
4,393
32
4,406
366
Deferred taxes
-1,320
-12
-433
-765
Share-based compensation expense
249
272
225
201
Benefit plan contributions in excess of expense/income
112
173
368
84
Inventory write-offs and related charges associated with covid-19 products
-
-
0
-
Net gain from the sale of investment in viiv
1,870
-
-
-
Other adjustments, net
66
93
117
292
Trade accounts receivable
-
-
263
-
Inventories
-
-
-561
-
Other assets
-
-
-1,289
-
Trade accounts payable
-
-
-469
-
Other liabilities
-
-
-3,667
-
Other tax accounts, net
-
-
-2,805
-
Other changes in assets and liabilities, net of acquisitions and divestitures
1,816
-5,212
-
36
Net cash provided by/(used in) operating activities
835
2,615
5,348
4,603
Purchases of property, plant and equipment
533
436
845
602
Purchases of short-term investments
2,544
2,569
4,048
4,223
Proceeds from redemptions/sales of short-term investments
2,038
4,576
4,723
2,736
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less
-1,178
792
-576
583
Purchases of long-term investments
-9
104
79
129
Proceeds from redemptions/sales of long-term investments
84
88
591
359
Proceeds from sales of investment in haleon
-
0
0
0
Proceeds from sale of investment-Viiv Healthcare Limited
1,875
-
-
-
Acquisitions of businesses, net of cash acquired
-
-
6,927
-
Proceeds from sale of investment-Haleon
0
-
-
-
Other investing activities, net
1
-22
137
-14
Net cash provided by/(used in) investing activities
2,106
785
-6,146
-2,430
Proceeds from short-term borrowings
-
-
0
0
Payments on short-term borrowings
0
0
0
0
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less
64
-127
101
6
Proceeds from issuance of long-term debt
0
-
5,991
0
Payments on long-term debt
1,250
-
3,007
0
Cash dividends paid
2,451
2,445
2,445
2,444
Other financing activities, net
-27
-284
-43
-38
Net cash provided by/(used in) financing activities
-3,663
-2,856
596
-2,477
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
-4
19
5
2
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents
-727
563
-196
-301
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period
1,760
1,197
1,481
1,481
Cash and cash equivalents and restricted cash and cash equivalents, at end of period
1,034
1,760
1,197
1,394
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from
redemptions/sales of short-term...
$2,038M
(-68.86%↓ Y/Y)
Proceeds from sale of
investment-Viiv Healthcare...
$1,875M
Asset write-offs and
impairments
$4,393M
(2752.60%↑ Y/Y)
Net (purchases
of)/proceeds from...
-$1,178M
(0.51%↑ Y/Y)
Proceeds from
redemptions/sales of long-term...
$84M
(33.33%↑ Y/Y)
Purchases of long-term
investments
-$9M
(81.25%↑ Y/Y)
Depreciation and
amortization
$1,622M
(-0.18%↓ Y/Y)
Share-based compensation
expense
$249M
(22.66%↑ Y/Y)
Net cash provided
by/(used in) investing...
$2,106M
(-46.70%↓ Y/Y)
Net cash provided
by/(used in) operating...
$835M
(243.47%↑ Y/Y)
Canceled cashflow
$3,078M
Canceled cashflow
$5,430M
Net
increase/(decrease) in cash and cash...
-$727M
(-441.31%↓ Y/Y)
Canceled cashflow
$2,941M
Net (payments
on)/proceeds from short-term...
$64M
(112.38%↑ Y/Y)
Purchases of short-term
investments
$2,544M
(-22.01%↓ Y/Y)
Purchases of property,
plant and equipment
$533M
(-13.75%↓ Y/Y)
Other investing
activities, net
$1M
(-91.67%↓ Y/Y)
Net gain from the
sale of investment in...
$1,870M
Other changes in
assets and...
$1,816M
(-63.60%↓ Y/Y)
Deferred taxes
-$1,320M
(-385.29%↓ Y/Y)
Net income from
continuing operations...
-$246M
(-108.47%↓ Y/Y)
Benefit plan
contributions in excess of...
$112M
(6.67%↑ Y/Y)
Other adjustments,
net
$66M
(-34.65%↓ Y/Y)
Net cash provided
by/(used in) financing...
-$3,663M
(-14.61%↓ Y/Y)
Canceled cashflow
$64M
Effect of
exchange-rate changes on cash...
-$4M
(-109.76%↓ Y/Y)
Cash dividends paid
$2,451M
(0.25%↑ Y/Y)
Payments on long-term
debt
$1,250M
(-66.67%↓ Y/Y)
Other financing
activities, net
-$27M
(-28.57%↓ Y/Y)
Buy us a coffee
Pfizer_(2021)-svg
PFIZER INC (PFE)
Pfizer_(2021)-svg
PFIZER INC (PFE)
Show more